Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | C5AR1 | P21730 | 13/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15987294 | 0.88 | C5AR1 (0.47) | SIGMAR1C5AR1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL9998686 | 0.86 | CCR5 (0.50) | CCR5C5AR1 | |
| SCHEMBL803680 | 0.85 | C5AR1 (0.56) | CCR5C5AR1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL15751249 | 0.85 | SIGMAR1 (0.53) | SIGMAR1CCR5ALDH1A1ENPP2 | |
| SCHEMBL1058888 | 0.84 | SIGMAR1 (0.60) | SIGMAR1CCR5ALDH1A1ENPP2 | |
| SCHEMBL9998607 | 0.84 | CCR5 (0.49) | CCR5C5AR1 | |
| SCHEMBL19048552 | 0.83 | C5AR1 (0.43) | SIGMAR1CCR5C5AR1ALDH1A1CYP2C9 | |
| SCHEMBL31734241 | 0.83 | SIGMAR1 (0.49) | SIGMAR1CCR5ALDH1A1ENPP2 | |
| SCHEMBL27866758 | 0.82 | SIGMAR1 (0.51) | SIGMAR1CCR5ALDH1A1ENPP2 | |
| SCHEMBL8029227 | 0.82 | SIGMAR1 (0.64) | SIGMAR1CCR5ALDH1A1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261327-A1 | 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation | MERCK & CO., INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261327-A1 | 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation | BDKRB1, BDKRB2, LTB4R2 | SIGMAR1 1107/4885CCR5 525/4885C5AR1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.